MEDINDIA
English
हिन्दी
Español
français
中文
Email
Browse the FDA Approved Drugs by Year
Browse 2022 FDA Approved Drugs by month
January
Abrocitinib
Abrocitinib is indicated for treating adults with refractory, moderate-to-severe atopic dermatitis whose disease is not properly controlled with other medications. The recommended dosage is 100 mg orally once daily The drug is not recommended for use in combination with drugs affecting the immune system like biologic immunomodulators, or with other immunosuppressants. Common side effects include nasopharyngitis, nausea, headache, herpes simplex, increased blood creatinine phosphokinase, dizziness, urinary tract infection, tiredness, etc.
Daridorexant
Daridorexant is approved by the USFDA for treating adults with sleeplessness or insomnia. Dosage form: 25 mg and 50 mg tablets The recommended daily dose is 25 mg to 50 mg once per night, taken orally within 30 minutes before going to bed. The drug is contraindicated in patients with narcolepsy or excessive sleepiness Daridorexant may impair alertness and motor coordination including morning impairment. The most common aside effects were headache and somnolence or fatigue
Faricimab
Faricimab is approved for treating age-related macular degeneration and diabetic macular edema. Age-related macular edema is the swelling of the internal part of the eye that occurs due to degenerative changes occurring with age. The recommended dose is 6 mg given by intravitreal injection every 4 weeks for the first 4 doses. After that, dosage depends on eye assessments. The drug should not be used for patients having eye infections, eye swelling and redness(inflammation), and allergies.
Tebentafusp
Tebentafusp is approved by the USFDA for treating adults with patients with unresectable or metastatic uveal melanoma. Uveal melanoma is cancer affecting the uvea-anterior part of the eye in which melanin cells multiply rapidly, The recommended dosage: 20 mcg intravenously on Day 1, 30 mcg intravenously on Day 8, 68 mcg intravenously on Day 15, and 68 mcg intravenously once every week. Common side effects caused by the drug are cytokine release syndrome, fever, skin rash, itching, tiredness, chills, abdominal pain, edema, hypotension, dry skin, headache, and vomiting
February
Mitapivat
Mitapivat is indicated for treating adults having anemia with an enzyme named is a pyruvate kinase deficiency. Dosage form: Tablets: 5 mg, 20 mg, and 50 mg. Starting dosage: 5 mg orally twice daily with or without food. Side effects reported in clinical trials were estrone decreased (males), increased urate, back pain, estradiol decreased (males), and bone pain. Patients with liver disorders should be cautious while using this medication.
Pacritinib
Pacritinib is approved for treating adults with myelofibrosis (a disorder of bone marrow) with a platelet count below 50 × 109/L (1). The drug is available as a capsule in a dose of 100mg. The recommended dosage is 200 mg orally twice daily. Common side effects caused by medication include diarrhea, low platelet count, nausea, anemia, and ankle swelling.
Sutimlimab
Sutimlimab is approved by the USFDA to reduce the need for red blood cell transfusion due to hemolysis in cold agglutinin disease. Cold agglutinin disease is a form of anemia or low hemoglobin levels. The medication is available as an Injection: 1,100 mg/22 mL (50 mg/mL) in a single-dose vial Common side effects include respiratory tract infection, viral infection, diarrhea, dyspepsia, cough, arthralgia, arthritis, and ankle swelling.
March
Ganaxolone
Ganaxolone is approved under the trade name "ZTALMY" for treating seizures(fits) associated with an enzyme named cyclin-dependent kinase-like 5 (CDKL5) deficiency in patients aged 2 years and above. The medication is available as oral suspension Ganoxolone should be given orally three times daily with food. The dose should be increased slowly. The starting dosage is 18 mg/kg/day. The maximum dosage is 21 mg/kg three times daily. Most common side effects reported in clinical trials are excessive sleepiness, fever, salivary hypersecretion, and seasonal allergy.
Lutetium Lu 177
Lutetium Lu 177 is approved under the trade name "PLUVICTO". It is a radioligand therapeutic agent approved for treating prostate cancer. The drug should be given as 7.4 GBq (200 mCi) every 6 weeks for up to 6 doses. (2.3) Dosage form: Injection: 1,000 MBq/mL (27 mCi/mL) in a single-dose vial. Most common side effects reported are tiredness or fatigue, dry mouth, nausea, anemia, decreased appetite, and constipation. Most common laboratory abnormalities reported in clinical trials are decreased lymphocytes(white blood cells), decreased hemoglobin, decreased platelets, decreased calcium, and decreased sodium.
Nivolumab and Relatlimab
The combination of "Nivolumab and Relatlimab" is approved under the trade name "OPDUALAG". This combination is approved for the treatment of skin cancer named melanoma in patients aged 12 years and above. The dose is 480 mg nivolumab and 160 mg relatlimab to be injected into the vein every 4 weeks. The infusion should be given for 30 minutes. Common side effects reported are musculoskeletal pain, tiredness, itching, rash, pruritus, and diarrhea. The most common laboratory abnormalities are low hemoglobin, decreased lymphocytes(white blood cells), increased liver enzymes, and decreased sodium.
Oteseconazole
To reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are not of reproductive potential
Tirzepatide
To improve blood sugar control in diabetes, in addition to diet and exercise
Vonoprazan, amoxicillin, and clarithromycin
To treat Helicobacter pylori infection
September
Daxibotulinumtoixna-lanm
To treat moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity
Deucravacitinib
To treat moderate-to-severe plaque psoriasis
Eflapegrastim
To decrease the incidence of infection in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia
Futibatinib
To treat intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements
Gadopiclenol
To detect and visualize lesions, together with MRI, with abnormal vascularity in the central nervous system and the body
Oomidenepag isopropyl ophthalmic solution
To reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Sodium phenylbutyrate/taurursodiol
To treat amyotrophic lateral sclerosis (ALS)
Spesolimab-sbzo
To treat generalized pustular psoriasis flares
Terlipressin
To improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function
October
Teclistamab-cqyv
To treat relapsed or refractory multiple myeloma among adults who have received at least four specific lines of therapy
Tremelimumab
To treat unresectable hepatocellular carcinoma
November
Mirvetuximab soravtansine-gynx
To treat patients with recurrent ovarian cancer that is resistant to platinum therapy
Teplizumab-mzwv
To delay the onset of stage 3 type 1 diabetes
December
Adagrasib
To treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer in adults who have received at least one prior systemic therapy
Anacaulase-bcdb
To remove eschar in adults with deep partial thickness or full thickness thermal burns
Hyperpolarized xe-129
To evaluate pulmonary function and imaging
Lenacapavir
To treat adults with HIV whose HIV infections cannot be successfully treated with other available treatments due to resistance, intolerance, or safety considerations
Mosunetuzumab-axgb
To treat adults with relapsed or refractory follicular lymphoma, a type of non-Hodgkin lymphoma
Olutasidenib
To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation
Ublituximab-xiiy
To treat relapsing forms of multiple sclerosis
